Rivastigmine

Drug Profile

Rivastigmine

Alternative Names: ENA 713; ENA 713D; Exelon; Exelon Patch; Exelon TDS; ONO-2540; Prometax; Rivastach Patch; Rivastigmine transdermal system; SDZ 212713; SDZ ENA 713

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Developer Novartis; Ono Pharmaceutical
  • Class Antidementias; Phenylcarbamates; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Butyrylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alzheimer's disease; Dementia
  • Phase III Delirium

Most Recent Events

  • 01 Feb 2016 Novartis completes a phase III trial in Delirium (In the elderly) in France (NCT01487317)
  • 04 Sep 2015 First Generic equivalent of Exelon® Patch available in USA for Alzheimer's disease
  • 24 Aug 2015 Ono Pharmaceuticals receives approval for a one-step titration regimen for Alzheimer's disease in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top